|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Background/Aims:</b> MiR-145 and Smad2 have been widely reported in the development and progression of human malignancies.
|
31114250 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusion:</b> These findings suggested that miR-145 can inhibit HOXA1 to inactivate the ERK/MAPK signaling pathway, thereby suppressing OSCC cell proliferation, migration, and invasion to further inhibit the development of OSCC, highlighting a novel therapeutic target for the OSCC treatment.
|
31138758 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusion:</b> These results suggested that CDX2 inhibits the expression of miR-145-5p, thereby relieving the inhibitory effect of miR-145-5p on the translation of SENP1 and affecting the invasion and migration of prostate cancer cells.
|
31249806 |
2019 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Patients and methods:</b> qRT-PCR was used to determine the expression of miR-145 in glioma patients and GSCs, and GSCs were transfected with miR-145 overexpressed vectors.
|
31440081 |
2019 |
|
Laryngeal Squamous Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> MiR-145 inhibited LSCC growth in a dose-dependent manner, as tumor growth was significantly inhibited in mice injected intratumorally with high-dose miR-145 compared with both the untreated and low-dose miR-145 groups (<i>p</i><0.05).
|
31118798 |
2019 |
|
Hypertensive disease
|
0.050 |
AlteredExpression
|
group |
BEFREE |
<b>Results:</b> Comparative with control group, in hypertension associated with hyperlipidemia the investigated miRNA expression profiles were different: (i) in plasma, the levels of all investigated miRNAs were significantly increased, the highest enhances being noticed for miR-21,-146a,-221,-143,-34a, and miR-204; (ii) in platelets, the expressions of almost all miRNAs were significantly elevated, remarkable for miR-126,-146a,-223,-222, and miR-214, while levels of miR-143, miR-10a, and miR-145 were significantly reduced; (iii) in PMVs, numerous miRNAs were found to have significantly increased levels, especially miR-222,-221,-210, and miR-34a, whereas expressions of various miRNAs as miR-223,-214,-146a,-143,-10a, and miR-145 were significantly decreased.
|
31850358 |
2019 |
|
Hyperlipidemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> Comparative with control group, in hypertension associated with hyperlipidemia the investigated miRNA expression profiles were different: (i) in plasma, the levels of all investigated miRNAs were significantly increased, the highest enhances being noticed for miR-21,-146a,-221,-143,-34a, and miR-204; (ii) in platelets, the expressions of almost all miRNAs were significantly elevated, remarkable for miR-126,-146a,-223,-222, and miR-214, while levels of miR-143, miR-10a, and miR-145 were significantly reduced; (iii) in PMVs, numerous miRNAs were found to have significantly increased levels, especially miR-222,-221,-210, and miR-34a, whereas expressions of various miRNAs as miR-223,-214,-146a,-143,-10a, and miR-145 were significantly decreased.
|
31850358 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Results:</b> MiR-145 inhibited LSCC growth in a dose-dependent manner, as tumor growth was significantly inhibited in mice injected intratumorally with high-dose miR-145 compared with both the untreated and low-dose miR-145 groups (<i>p</i><0.05).
|
31118798 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon.
|
25477374 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth delay assays and survival curves were then analyzed in an animal model to investigate whether miR-145 induced radiosensitivity in vivo.
|
26632856 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
|
30370446 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
miR-145 inhibits breast cancer cell growth through RTKN.
|
19360360 |
2009 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
miR-145 inhibits breast cancer cell growth through RTKN.
|
19360360 |
2009 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors.
|
19915607 |
2010 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors.
|
19915607 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer.
|
20160723 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MicroRNA-145 (miR-145), an important member in the family of microRNAs, is under-expressed in several types of tumors and acts as a tumor suppressor.
|
22472569 |
2012 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
MiR-145 may represent a potential therapeutic target for treatment of oxidative stress-associated cardiovascular diseases, such as myocardial ischemia/reperfusion injury.
|
23028672 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-145 also inhibited N-RAS and IRS1 expression to suppress AKT and ERK1/2 activation, and VEGF expression in mouse xenograft tumors.
|
23201159 |
2013 |
|
Secondary malignant neoplasm of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
MiR-145, a direct target of p53, represses bone metastasis of PCa and is involved in regulating EMT and cancer cell stemness.
|
23404342 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients.
|
23441135 |
2013 |
|
Renal Cell Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients.
|
23441135 |
2013 |
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
miR-145 is under-expressed in low-grade, non-invasive and high-grade invasive urothelial bladder carcinoma and may play an important role in the carcinogenesis pathway, being an interesting candidate diagnostic marker.
|
23489501 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
|
23499894 |
2013 |
|
Malignant neoplasm of liver
|
0.230 |
Biomarker
|
disease |
BEFREE |
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
|
23499894 |
2013 |